Kevane Christopher E.

Chief Legal Officer sold 23.7K shares of UTI at $37.55; prior pattern shows 100% well-timed sells at 90-day horizon

Kevane Christopher E., EVP and Chief Legal Officer, sold 23,654 shares at $37.55 on 2026-03-27, reducing his holdings by -22.1% to 83,521 shares. His prior sales at UTI (both on 2025-05-12) demonstrated consistent positive timing: the first showed -21.3% 90-day return, the second -24.2% 90-day return, indicating the stock declined after he sold both times. His cross-ticker track record reinforces this pattern, with a 90d well-timed rate of 100.00% across 2 prior sells. The current price of $36.10 is now -9.0% from the 52-week high of $39.66, and only -0.3% below where he executed this sale 30 days ago, suggesting the timing signal remains an open question at the intermediate horizon.

UTI EVP/Chief Legal Officer sells 29,400 shares ($1.0M) near 52-week high, reducing stake 28.5%

Kevane Christopher E., EVP and Chief Legal Officer, sold 29,400 shares (29.4K shares) for $1,003,261.00 ($1.0M) via two separate transactions on 2025-05-12, reducing his holdings from 103,077 shares to 73,677 shares (103.1K to 73.7K shares, a -28.5% reduction). The blended average sale price of $34.12 is near the 52-week high of $34.33, within 0.61% of the peak. The stock is currently at $33.10, having gained 20.8% over 30 days and 21.7% over 90 days, reflecting strong recent momentum in a company with P/E of 31.23 and annual revenue growth of +20.6%. A substantial reduction in insider holdings by a chief legal officer at a point near the 52-week high, following sharp recent price appreciation, is a material shift in position exposure that warrants monitoring for its informational content relative to company prospects.